Equities research analysts predict that Kala Pharmaceuticals Inc (NASDAQ:KALA) will report $960,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Kala Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.72 million and the lowest estimate coming in at $500,000.00. The business is expected to issue its next earnings results on Thursday, May 9th.

According to Zacks, analysts expect that Kala Pharmaceuticals will report full year sales of $14.42 million for the current year, with estimates ranging from $11.17 million to $20.00 million. For the next fiscal year, analysts forecast that the business will post sales of $68.92 million, with estimates ranging from $38.90 million to $94.71 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last announced its earnings results on Monday, March 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.23).

A number of equities analysts recently weighed in on KALA shares. Zacks Investment Research lowered shares of Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, March 26th. BidaskClub upgraded shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, February 20th. ValuEngine lowered shares of Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Wedbush set a $51.00 price objective on shares of Kala Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, January 16th. Finally, Jefferies Financial Group started coverage on shares of Kala Pharmaceuticals in a research report on Thursday, March 14th. They issued a “buy” rating and a $15.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $20.58.

NASDAQ:KALA traded down $0.02 during midday trading on Monday, reaching $7.60. The stock had a trading volume of 139,663 shares, compared to its average volume of 217,404. Kala Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $17.39. The company has a debt-to-equity ratio of 0.67, a current ratio of 10.41 and a quick ratio of 10.17. The firm has a market cap of $257.51 million, a price-to-earnings ratio of -3.06 and a beta of 1.73.

Institutional investors have recently added to or reduced their stakes in the business. American International Group Inc. raised its stake in shares of Kala Pharmaceuticals by 34.3% during the 4th quarter. American International Group Inc. now owns 10,369 shares of the company’s stock worth $51,000 after buying an additional 2,646 shares during the last quarter. Squarepoint Ops LLC lifted its position in Kala Pharmaceuticals by 12.4% during the 4th quarter. Squarepoint Ops LLC now owns 27,871 shares of the company’s stock worth $136,000 after acquiring an additional 3,071 shares in the last quarter. Wedbush Securities Inc. lifted its position in Kala Pharmaceuticals by 4.0% during the 4th quarter. Wedbush Securities Inc. now owns 120,509 shares of the company’s stock worth $589,000 after acquiring an additional 4,690 shares in the last quarter. United Services Automobile Association lifted its position in Kala Pharmaceuticals by 33.6% during the 4th quarter. United Services Automobile Association now owns 24,218 shares of the company’s stock worth $118,000 after acquiring an additional 6,088 shares in the last quarter. Finally, Rhumbline Advisers acquired a new position in Kala Pharmaceuticals during the 4th quarter worth approximately $75,000. 67.20% of the stock is owned by institutional investors.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

See Also: Understanding Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.